NO973023D0 - Fremgangsmåte og sammensetninger for behandling av allergisk rhinitt og andre forstyrrelser ved anvendelse av deskarboetoksyloratadin - Google Patents

Fremgangsmåte og sammensetninger for behandling av allergisk rhinitt og andre forstyrrelser ved anvendelse av deskarboetoksyloratadin

Info

Publication number
NO973023D0
NO973023D0 NO973023A NO973023A NO973023D0 NO 973023 D0 NO973023 D0 NO 973023D0 NO 973023 A NO973023 A NO 973023A NO 973023 A NO973023 A NO 973023A NO 973023 D0 NO973023 D0 NO 973023D0
Authority
NO
Norway
Prior art keywords
allergic rhinitis
descarboethoxyloratadine
disorders
compositions
treatment
Prior art date
Application number
NO973023A
Other languages
English (en)
Other versions
NO317555B1 (no
NO973023L (no
Inventor
A K Gunnar Aberg
John R Mccullough
Emil R Smith
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23443929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO973023(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of NO973023D0 publication Critical patent/NO973023D0/no
Publication of NO973023L publication Critical patent/NO973023L/no
Publication of NO317555B1 publication Critical patent/NO317555B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19973023A 1994-12-30 1997-06-27 Fremgangsmate og preparater for behandling av allergisk rhinitt og andre forstyrrelser ved anvendelse av deskarboetoksyloratadin NO317555B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/366,651 US5595997A (en) 1994-12-30 1994-12-30 Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
PCT/US1995/015995 WO1996020708A1 (en) 1994-12-30 1995-12-11 Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Publications (3)

Publication Number Publication Date
NO973023D0 true NO973023D0 (no) 1997-06-27
NO973023L NO973023L (no) 1997-08-19
NO317555B1 NO317555B1 (no) 2004-11-15

Family

ID=23443929

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19973023A NO317555B1 (no) 1994-12-30 1997-06-27 Fremgangsmate og preparater for behandling av allergisk rhinitt og andre forstyrrelser ved anvendelse av deskarboetoksyloratadin
NO20020211A NO330421B1 (no) 1994-12-30 2002-01-15 Anvendelse av deskarboksyloratadin for fremstilling av et farmasoytisk preparat for behandling av allergisk astma
NO20110077A NO20110077L (no) 1994-12-30 2011-01-18 Anvendelse av deskarboetoksyloratadin for fremstilling av et farmasoytisk preparat for behandling av medisinske tilstander

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20020211A NO330421B1 (no) 1994-12-30 2002-01-15 Anvendelse av deskarboksyloratadin for fremstilling av et farmasoytisk preparat for behandling av allergisk astma
NO20110077A NO20110077L (no) 1994-12-30 2011-01-18 Anvendelse av deskarboetoksyloratadin for fremstilling av et farmasoytisk preparat for behandling av medisinske tilstander

Country Status (22)

Country Link
US (2) US5595997A (no)
EP (3) EP1078633A3 (no)
JP (1) JP4237822B2 (no)
KR (1) KR100442675B1 (no)
CN (2) CN1935141B (no)
AT (1) ATE339956T1 (no)
AU (1) AU707541B2 (no)
BR (1) BR9510129A (no)
CA (1) CA2208836C (no)
CZ (1) CZ293068B6 (no)
DE (2) DE69535234T2 (no)
DK (1) DK0799037T3 (no)
ES (1) ES2144980T3 (no)
FI (1) FI972781A (no)
HK (1) HK1008185A1 (no)
HU (1) HU229871B1 (no)
MX (1) MX9704793A (no)
NO (3) NO317555B1 (no)
NZ (1) NZ300398A (no)
PT (1) PT799037E (no)
SK (3) SK286079B6 (no)
WO (1) WO1996020708A1 (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219462B (hu) * 1993-06-14 2001-04-28 Janssen Pharmaceutica N.V. Asztemizolt és pszeudoefedrint tartalmazó, nyújtott hatású, filmbevonatos tabletták
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US7214683B1 (en) * 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US7211582B1 (en) * 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
IL125446A0 (en) * 1996-02-08 1999-03-12 Merck & Co Inc Pharmaceutical composition for the treatment of asthma allergy and inflammation
KR20000052922A (ko) * 1996-10-31 2000-08-25 둘락 노먼 씨. 로라타딘 및 충혈제거제를 함유하는 천식 치료용 조성물
US6324267B1 (en) 1997-01-17 2001-11-27 Scientific-Atlanta, Inc. Two-tiered authorization and authentication for a cable data delivery system
PE71699A1 (es) * 1997-02-07 1999-08-03 Sepracor Inc Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
AU776837B2 (en) * 1997-02-07 2004-09-23 Sunovion Pharmaceuticals Inc. Lactose-free non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
EP1041990B1 (en) * 1997-12-23 2006-06-28 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6140337A (en) * 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
ATE274907T1 (de) * 1998-06-30 2004-09-15 Pfizer Prod Inc Loratadin zur verwendung als antiarrhythmikum
AU741201B2 (en) * 1998-07-10 2001-11-22 Merck Sharp & Dohme Corp. 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6) cyclohepta (1,2-b)pyridine oral compositions
PE20001070A1 (es) * 1998-09-10 2000-10-19 Schering Corp Metodos y composiciones para tratar sinusitis, otitis media y otros desordenes relacionados usando antihistaminas
AU3924500A (en) * 1999-03-29 2000-10-16 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
AR025711A1 (es) * 1999-09-21 2002-12-11 Schering Corp El uso de la desloratadina para la preparacion de un medicamento para tratar y prevenir estados alergicos e inflamatorios
JP2003509459A (ja) * 1999-09-22 2003-03-11 シェーリング コーポレイション アレルギー状態および炎症状態の処置
AU7859800A (en) * 1999-10-08 2001-04-23 Schering Corporation Topical nasal treatment
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
WO2001045688A2 (en) * 1999-12-21 2001-06-28 Schering Corporation Use od desloratadine for treating allergic and inflammatory conditions in pediatric patients
US7405223B2 (en) * 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
CN1213752C (zh) * 2000-02-03 2005-08-10 先灵公司 变应性和炎性疾病的治疗
AU2001255268A1 (en) * 2000-04-07 2001-10-23 Schering Corporation Inhibition of cytokine generation
WO2002067938A2 (en) * 2000-10-30 2002-09-06 Schering Corporation Treating or reducing the risk of cardiovascular disease
WO2002036124A2 (en) * 2000-10-30 2002-05-10 Schering Corporation Treatment and method using loratadine and montelukast
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US6599914B2 (en) * 2001-04-24 2003-07-29 Schering Corporation Inhibition of cytokine generation
US20030236275A1 (en) * 2002-06-20 2003-12-25 Schering Corporation Treatment methods of nasal congestion and nasal obstruction
US6720002B2 (en) * 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
EP1437130A4 (en) * 2001-10-17 2009-08-26 Hisamitsu Pharmaceutical Co PERCUTANEOUS ABSORPTION PREPARATIONS
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
BR0214643A (pt) * 2001-12-05 2004-11-03 Alcon Inc Aplicação de um antagonista h1, e um esteróide seguro para tratar rinite
US20030004179A1 (en) * 2002-05-21 2003-01-02 Affrime Melton B Treating allergic and inflammatory conditions
CN1674901A (zh) * 2002-08-05 2005-09-28 桑多斯股份公司 新的地氯雷他定半富马酸盐及其多晶型物
AU2002334383A1 (en) * 2002-09-24 2004-04-19 Morepen Laboratories Limited An improved process for the production of desloratadine
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
EP1817307A2 (en) * 2004-07-07 2007-08-15 Egis Gyogyszergyar Rt. New pseudopolymorph of desloratadine formed with carbon dioxide
MX2007000632A (es) * 2004-07-16 2007-03-30 Cipla Ltd Composicion antihistaminica.
US20060154948A1 (en) * 2005-01-12 2006-07-13 Schering Corporation Treating allergic and inflammatory conditions
CA2541045A1 (en) * 2006-03-24 2007-09-24 Pharmascience Inc. A descarbonylethoxyloratadine containing pharmaceutical composition
BRPI0712532A2 (pt) 2006-06-01 2013-04-02 Schering Plough Healthcare Prod Inc formulaÇÕes e composiÇÕes farmacÊuticas de fenilefrina para absorÇço colânica
US20080207593A1 (en) * 2007-02-28 2008-08-28 Collegium Pharmaceutical, Inc. Antihistamine Combination
US20090054338A1 (en) * 2007-08-06 2009-02-26 Aberg A K Gunnar Synergisms between repartitioning and immunomodulating compounds
CA2704728A1 (en) * 2007-09-18 2009-03-26 Stephen Wills Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors
US8321151B2 (en) 2008-12-30 2012-11-27 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8073633B2 (en) * 2008-12-30 2011-12-06 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8315815B2 (en) 2008-12-30 2012-11-20 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
TW201111392A (en) 2009-06-16 2011-04-01 Schering Corp Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
EP2269586B1 (en) 2009-07-01 2011-09-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising desloratadine
CA2690490C (en) 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
US8557846B1 (en) 2012-10-23 2013-10-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in dogs
US8778971B2 (en) 2012-10-23 2014-07-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in companion animals
US20140120121A1 (en) 2012-10-30 2014-05-01 Bridge Pharma, Inc. Medicinal treatment of atopic inflammatory diseases
US20150272941A1 (en) 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
US9345697B2 (en) 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
US9439895B2 (en) 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
US9138431B2 (en) 2013-08-06 2015-09-22 Bridge Pharma, Inc. Methods of treatment of histamine H-4 receptor-related pruritus
IT201900012645A1 (it) * 2019-07-23 2021-01-23 Eros Zanotti Una composizione farmaceutica per l'uso nel trattamento delle chinetosi

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
JPS61501205A (ja) * 1984-02-15 1986-06-19 シェリング・コ−ポレ−ション ８↓−クロル↓−６，１１↓−ジヒドロ↓−１１↓−（４↓−ピペリジリデン）↓−５Ｈ↓−ベンゾ〔５，６〕シクロヘプタ〔１，２−ｂ〕ピリジンおよびその塩、これらの化合物の製造方法、ならびにこれらの化合物を含有する医薬組成物
US4804666A (en) * 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
IL98572A (en) * 1990-06-22 1995-07-31 Schering Corp Bite-benzo or benzopyrido compounds Cyclohepta piperidine, piperidylidene and piperazine, preparations and methods of use.
CA2098198A1 (en) * 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance

Also Published As

Publication number Publication date
HUT77315A (hu) 1998-03-30
SK88897A3 (en) 1998-02-04
SK284834B6 (sk) 2005-12-01
CN1935141B (zh) 2013-04-24
NO20020211D0 (no) 2002-01-15
NZ300398A (en) 2001-04-27
DE69535234D1 (de) 2006-11-02
AU4512696A (en) 1996-07-24
HK1008185A1 (en) 1999-05-07
CZ293068B6 (cs) 2004-02-18
BR9510129A (pt) 1997-12-30
ATE339956T1 (de) 2006-10-15
EP0799037B1 (en) 2006-09-20
US5731319A (en) 1998-03-24
PT799037E (pt) 2006-12-29
EP1078633A3 (en) 2001-03-07
US5595997A (en) 1997-01-21
EP0799037A4 (en) 1998-05-06
NO20110077L (no) 1997-08-19
HU229871B1 (en) 2014-11-28
KR100442675B1 (ko) 2004-10-14
FI972781A (fi) 1997-08-27
AU707541B2 (en) 1999-07-15
WO1996020708A1 (en) 1996-07-11
DE69535234T2 (de) 2007-09-13
NO317555B1 (no) 2004-11-15
JPH10512240A (ja) 1998-11-24
CN1176598A (zh) 1998-03-18
EP1078633A2 (en) 2001-02-28
DE799037T1 (de) 2000-10-05
CZ202697A3 (cs) 1998-03-18
CN1267098C (zh) 2006-08-02
JP4237822B2 (ja) 2009-03-11
NO20020211L (no) 1997-08-19
CA2208836A1 (en) 1996-07-11
ES2144980T1 (es) 2000-07-01
FI972781A0 (fi) 1997-06-27
EP0799037A1 (en) 1997-10-08
NO973023L (no) 1997-08-19
SK286079B6 (sk) 2008-03-05
DK0799037T3 (da) 2007-02-12
CN1935141A (zh) 2007-03-28
EP1712232A1 (en) 2006-10-18
ES2144980T3 (es) 2007-03-16
CA2208836C (en) 2001-12-04
SK287257B6 (sk) 2010-05-07
MX9704793A (es) 1997-10-31
NO330421B1 (no) 2011-04-11

Similar Documents

Publication Publication Date Title
NO973023D0 (no) Fremgangsmåte og sammensetninger for behandling av allergisk rhinitt og andre forstyrrelser ved anvendelse av deskarboetoksyloratadin
HUP9904362A2 (hu) Eljárás felső légúti allergiás tünetek kezelésére hisztamin H1 és H3 receptor-antagonisták kombinációjával
BR0014912A (pt) Tratamento de distúrbios do sono usando desloratadina
HK1075456A1 (en) Glp-1 and methods for treating diabetes glp-1(1)
CY1105199T1 (el) Θepαπευτικες συνθεσεις για αντιμετωπιση της υπepεκκρισης βλεννας
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
NO307546B1 (no) Farmasøytisk preparat inneholdende optisk ren R-ketorolak samt anvendelse derav
GB2285219B (en) Use of norastemizole for the treatment of allergic disorders
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
SI0652000T1 (en) Use of 2-phenyl-3-aroylbenzothiophenes for the preparation of a medicament for inhibiting angiogenisis and angiogenic diseases
DE69111974T2 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
Pallone et al. Lansoprazole and Helicobacter pylori infection
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
Moon et al. Effects of KakamBoyanghwanohTang (KBT) on inhibition of impairment of learning and memory, and acetylcholinesterase in amnesia mice
RU93057107A (ru) Способ лечения рефлюкс-эзофагита у больных бронхиальной астмой с помощью инфракрасного лазера
NO881798D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
RU93008441A (ru) Способ длительной антистрессорной терапии у хирургических больных
RU2002116180A (ru) Способ лечения сенильной макулярной дистрофии сетчатки

Legal Events

Date Code Title Description
MK1K Patent expired